Bitler and colleagues used an EZH2 inhibitor (GSK126) to treat ARID1A-loss OCCC cells and found that ARID1A mutation status correlated with the response of tumor cells to EZH2 inhibitors [48]. This evidence concerns the gene ARID1A and neoplasm.